Tepezza

Centralized before Judge Thomas M. Durkin in the Northern District of Illinois in June 2023, the Tepezza litigation consolidates federal claims that teprotumumab, marketed as Tepezza for thyroid eye disease, caused permanent or long-term hearing loss and tinnitus, allegedly without adequate warning to patients and prescribers. With 277 total actions pending, this docket sits at a genuinely uncertain procedural juncture: bellwether trial deadlines that had structured the litigation's path toward its first trial were struck in October 2025, and the hearing-loss trial date was subsequently pushed to August 2026.

That scheduling disruption is itself a meaningful structural signal, even though its cause has not been publicly confirmed. Deadlines are struck for a range of reasons in mass tort litigation — genuine settlement negotiations, unresolved discovery disputes, or case-management complications unrelated to settlement — and observers have speculated that this change may reflect movement toward a negotiated resolution, though no settlement has been announced. What the delay concretely establishes is that the original bellwether-to-verdict timeline this docket was following is no longer operative, and a new trial date nearly a year later has taken its place.

For anyone assessing this docket's structure, the relevant near-term marker to watch is whether the parties file a joint status report, settlement-related motion, or amended case-management order that clarifies the reason for the schedule change — that filing, whenever it comes, will do more to establish this docket's actual trajectory than the scheduling shift alone. Criterica Intelligence's platform tracks these kinds of procedural inflection points — deadline changes, trial-date shifts, and their eventual resolution — across every active MDL, without asserting a settlement outcome ahead of confirmed developments.